INTRODUCTION AND OBJECTIVES:
The melanoma-associated antigen-A (MAGE-A) family is a highly attractive target for cancer immunotherapy because of its broad representation in cancer tissues but restricted expression in normal tissues. Recent studies have shown significant expression of MAGE A antigen in urothelial carcinoma (UC). We aim to assess MAGE A and Programmed Death-Ligand 1 (PD-L1) expression in a large UC cohort spanning multiple grades, stages, and including metastatic disease to inform immunotherapeutic approaches to the treatment of UC.
METHODS: Analysis of MAGE A and PD-L1 expression on neoplastic cells using immunohistochemical staining of tissue microarrays from patients with bladder cancer (T1-4, Nx, M0-1) was done using the H-score system (a measure that simultaneously accounts for frequency and intensity of expression). We compared differential expression as well as H-scores between superficial vs. invasive, low (LG) vs. high grade (HG) as well as localized (LO) (T1-2) vs. locally advanced (LA) (T3-4) and metastatic vs non-metastatic. Comparisons between groups were done using Student's T-test for continuous variables and Chi-Square for categorical variables.
RESULTS: There were a total of 443 cases, of which 40% stained positively for MAGE A. Furthermore, 26% of the cohort was > 50% positive for MAGE expression. Expression was positive in 36% of the LG vs. 64% of HG patients (p¼<0.001). Expression of MAGE was 48% in LO vs. 52% in LA (p¼0.02). Sub-stratifying by individual stage, pT2 had the highest expression (28%) and pT4 had the lowest (2%). Mean H-score for MAGE A between HG vs. LG was 59 vs. 30, respectively (p¼<0.001), Tis (15) vs. T1-4 (45) was also significant (p¼<0.001). LO vs. LA was not significant (p¼0.8), similarly metastatic vs. non-metastatic (p¼0.59). Mean H-score for PD-L1 was significantly higher in LA vs LO (26% vs. 10% p¼0.02), and in HG vs. LG (21% vs. 2% p¼<0.001). No significant difference was noted between metastatic vs. non-metastatic (p¼0.71). There was no significant correlation between MAGE and PD-L1 expression for HG (p¼0.08) or LA (p¼0.12).
CONCLUSIONS: This is the largest report of the expression of MAGE A antigen in urothelial carcinoma showing a significant expression in higher grade and stage urothelial carcinoma as well as significant proportion of patients with >50% positive expression. In conjunction with high PD-L1 expression in HG and LA these data support MAGE targeted immune interventions, including adoptive therapy with TCR engineered T cells for UC with or without combination with checkpoint inhibitor. 00 not otherwise specified (NOS) 00 urothelial carcinoma. MPUC has been previously shown to be associated with ERBB2 amplification and HER2 protein overexpression. However, the status and distribution of these findings within MP and NOS components of MPUC have not been addressed. Therefore, we evaluated the ERBB2/HER2 expression in MP and NOS components by FISH and IHC.
METHODS: We identified 44 cases of MPUC that had tissue available for FISH and IHC at our institute, of which an NOS component sufficient for both FISH and IHC was identified in 37 cases. We followed the updated ASCO/CAP Guidelines for breast cancer and as such amplification was defined by a HER2/CEP17 ratio of 2.0 or > 6 copies of the gene and HER2 overexpression was considered with IHC scores of 2þ and 3þ.
RESULTS: In urothelial tumors with both MP and NOS components (n ¼ 37), ERBB2 amplification in MP and NOS components was present in 25 and 16 cases respectively. ERBB2 amplification was significantly higher in the MP component compared to NOS component within the same tumor (67.57% vs. 43.24%, p ¼ 0.049). HER2 overexpression in MP and NOS components was present in 25 and 13 cases respectively. HER2 overexpression was significantly higher in the MP component compared to NOS component within the same tumor (67.56% vs. 35.13%, p ¼ 0.012). In addition, ERBB2 amplification strongly correlated with HER2 overexpression in both MP (rho ¼ 0.65, p<0.001) and NOS (rho ¼ 0.74, p<0.001) components. In this cohort (n ¼ 44), tumor stage and lymph node status were significant predictors for overall survival (p ¼ 0.01, <0.001 respectively). However, ERBB2 amplification and HER2 overexpression in MP component were not associated with patients 0 survival outcome (p¼1.00, 0.75 respectively).
CONCLUSIONS: The majority of MPUC is associated with ERBB2 amplification and HER2 overexpression. In MPUC, ERBB2 amplification and HER2 overexpression were preferentially but not exclusively identified in MP component compared to NOS component. Our findings provide evidence for intratumoral heterogeneity of ERBB2 amplification and HER2 expression in MPUC. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e637
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MP48-04 EXPRESSION AND FUNCTION OF LYSOPHOSPHATIDIC ACID RECEPTOR 1 IN BLADDER CANCER
masao kataoka*, tomoyuki koguchi, Michihiro Yabe, Yuuichi Satoh, Nobuhiro Haga, Kei Ishibashi, Ken Aikawa, Yoshiyuki Kojima, Fukushima, Japan INTRODUCTION AND OBJECTIVES: Lysophosphatidic acid (LPA) is one of several physiologically active lipid mediators that promote cell proliferation, cell migration, and cell invasion and are present in serum, ascites, and urine. LPA receptor is considered a potential therapeutic target for treatment of some malignant cancers. Here, we evaluated the expression of LPA receptors, and effect of its receptor expression on recurrence, progression and survival rate in bladder cancer. Furthermore, we examined the bladder cancer invasion mechanism that LPA were associated.
METHODS: Expression of LPA receptors in bladder cancer specimens from bladder cancer patients (Ta or T1; 49 patients and T2-T4; 17 patients) was examined using real-time PCR and immunohistochemical staining. Matrigel invasion assay, proliferation assay, cell morphological observations were conducted and Rho kinase (ROCK) expression, myosin light chain (MLC) phosphorylation were measured to assess the effects of LPA on T24 cells, which derive from bladder cancer.
RESULTS: LPA receptor 1 (LPA1) mRNA expression was significantly higher in muscle-invasive bladder cancer (MIBC) specimens than in non-muscle-invasive bladder cancer (NMIBC) specimens. Strong LPA1 expression was evident on cell membranes of MIBC specimens. Cancer-specific survival rate was predominantly lower in LPA1 positive group. T24 cell invasion was increased by LPA treatment, and invasiveness was decreased by LPA1-siRNA or LPA1 inhibitor. LPA treatment increased Rho kinase1 (ROCK1) expression and phosphorylation of MLC, and induced morphological changes including lamellipodia formation and cell rounding.
CONCLUSIONS: Our results indicated that LPA1 expression was increased in bladder cancer with highly invasive potential. Furthermore, LPA signaling via LPA1 activation promoted bladder cancer invasion. Analyzing LPA1 expression might be useful for planning of bladder cancer treatment, and LPA1 can be a new therapeutic target for highly invasive bladder cancer.
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INTRODUCTION AND OBJECTIVES:
The coiled coil is a superhelical structural protein motif involved in a diverse array of biological functions, and the abnormal expression of the coiled-coil domain containing proteins has a direct link with the phenotype of tumor cell migration, invasion and metastasis. Here, we first reported the oncogenic roles of Coiled-coil domain-containing protein 34 (CCDC34), and investigated its biological functions in bladder carcinogenesis.
METHODS: Immunohistochemical staining and western blot were used to detect CCDC34 expression in bladder cancers specimens and cell lines. Lentivirus-mediated RNA interference and overexpression strategies were used to assess the effects of CCDC34 expression on various malignant phenotypes. The biological functions of CCDC34 knockdown on cells (T24 and 5637) were investigated by examining cell proliferation using a high content screening assay (HCS), BrdU incorporation assay and colony formation assay, cell migration by in vitro wound healing assay, cell invasion by Transwell invasion assay, as well as cell cycle distribution and apoptosis by flow cytometry. The expressions of Bcl-2, c-Raf, c-Jun, N-cadherin and Ecadherin as well as the phosphorylation of MEK, ERK1/2 and AKT were also measured using Western blot. We further investigated the effect of therapeutic siRNA targeting CCDC34 on T24 xenograft tumor growth in nude mice.
RESULTS: CCDC34 was up-regulated in human bladder cancer tissues and cell lines. CCDC34 was distributed mainly in the cytoplasm, and its expression was closely correlated with histological type, tumor grade and pathologic stage (n¼87, P<0.05). Besides, Western blot confirmed that CCDC34 was expressed at higher level in human bladder cancer tissues compared with their paraneoplastic normal bladder tissues (n¼18, P¼0.012). Knockdown of CCDC34 significantly suppressed bladder cancer cells proliferation, migration and invasion (P<0.01), and induced cell cycle arrest at G2/M phase and increased apoptosis in vitro (P<0.01). Moreover, CCDC34 knockdown decreased phosphorylation of MEK, ERK1/2 and AKT, and the expressions of cRaf, c-Jun and Bcl-2; while CCDC34 overexpression in T24 cells promoted cell migration and invasion with increased EMT, and treatment with MAPK/ERK1/2 and PI3K/AKT inhibitors blocked the phosphorylation of ERK1/2 and AKT, respectively. In addition, knockdown of CCDC34 suppressed bladder cancer cell growth in nude mice. CONCLUSIONS: Our findings revealed for the first time a potential oncogenic role for CCDC34 in bladder carcinoma pathogenesis, and activation of MAPK/ERK1/2 and PI3K/AKT signaling pathways was required for CCDC34 modulation of bladder cancer cell proliferation, migration and invasion. CCDC34 may serve as a biomarker or even a therapeutic target for bladder carcinoma.
